Harrow Inc. (HROW) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for HROW, including 2 press releases and news items and 1 earnings update. The most recent was published Nov 2, 2026.
HROW rankings
Financial highlights
Full financials- Revenue, TTM
- $275.59M
- Revenue growth
- +21.1%
- Net income, TTM
- -$37.23M
- Net margin
- -13.5%
- Free cash flow, TTM
- $5.02M
- Cash
- $83.89M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks350%
2026-05-102026-11-01
Mix1490d
- Other5(36%)
- SEC Filings4(29%)
- Earnings2(14%)
- Insider1(7%)
- Analyst1(7%)
- Leadership1(7%)
Latest news
25 items- PRPHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow’s Eye Care PortfolioPHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, to launch HarrowRx, Harrow’s new prescribing and access platform. HarrowRx gives eye care providers the ability to e-prescribe Harrow’s branded ophthalmic portfolio from one destination within the electronic medical record (EMR) systems they already use, with built-in patient services, ECP support, and affordability programs.One Prescribing Destination for Harrow’s Growing Eye Care PortfolioHarrowRx builds on the companies’ established partnership to improve patient access and affordability. Suppo
- PRHarrow Launches HarrowRx PlatformNASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a prescribing and access pharmacy platform that enables eyecare professionals to access Harrow’s entire portfolio directly within the electronic medical record (EMR) systems they already use. By connecting prescribing to product-specific fulfillment and patient-support services, HarrowRx is designed to make Harrow a more integrated part of a practice’s daily workflow. Harrow believes HarrowRx is the first platform of its kind developed by a U.S. ophthalmic pharmaceutical company. Today, prescribing
- PRHarrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2026, on Monday, November 9, 2026, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, November 10, 2026, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow’s presentation on th
- SECHarrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits8-K - HARROW, INC. (0001360214) (Filer)
- PRHarrow Closes Acquisition of TYRVAYA®NASHVILLE, Tenn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has closed its previously announced acquisition of TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. At closing, Harrow acquired worldwide rights to TYRVAYA, except for Japan. Viatris retained the rights to commercialize TYRVAYA in Japan and agreed to pay Harrow royalties on any future net sales there. Consistent with the terms announced in August, Harrow paid $30 million in cash at closing and may pay up to $70 million in contingent milestone payments tied to TYRVA
- PRHarrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAONASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at two major eyecare meetings: American Academy of Optometry’s (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim, California; andAmerican Academy of Ophthalmology’s (AAO) Annual Meeting, taking place October 9–12, 2026, in New Orleans, Louisiana. Harrow will have 13 presentations at AAOpt 2026 and two at AAO 2026, spanning dry eye disease, vernal keratoconjunctivitis (VKC), ocular inflammation,
- ANALYSTLeerink Partners initiated coverage on Harrow with a new price targetLeerink Partners initiated coverage of Harrow with a rating of Outperform and set a new price target of $45.00
- SECHarrow Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - HARROW, INC. (0001360214) (Filer)
- PRHarrow to Participate in Three Investor Conferences in SeptemberNASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following three investor conferences in September in New York, NY: 2026 Cantor Global Healthcare Conference Format: Fireside chat + 1x1 investor meetingsDate/Time: Wednesday, September 9, 2026, at 1:35 p.m. ET Lake Street Capital Markets 10th Annual Best Ideas Growth Conference Format: 1x1 investor meetingsDate/Time: Thursday, September 10, 2026 H.C. Wainwright 28th Annual Global Investment Conference Format: Fireside chat + 1x1 investor meetingsDate/Time: Tuesday, September 1
- PRHarrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal InjectionsNASHVILLE, Tenn., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study evaluating IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, an ophthalmic gel indicated for ocular surface anesthesia, in patients undergoing same-day bilateral intravitreal injections. The single-center, investigator-initiated study demonstrated statistically significant differences favoring IHEEZO at every measured time point. Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye than in the fellow eye treat
- INSIDERCHIEF SCIENTIFIC OFFICER Shojaei Amir exercised 11,250 shares at a strike of $35.96 and sold $450,000 worth of shares (11,250 units at $40.00) (SEC Form 4)4 - HARROW, INC. (0001360214) (Issuer)
- SECSEC Form 10-Q filed by Harrow Inc.10-Q - HARROW, INC. (0001360214) (Filer)
- SECHarrow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - HARROW, INC. (0001360214) (Filer)
- PRHarrow Announces Second Quarter 2026 Financial ResultsSecond Quarter 2026 and Selected Highlights: Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over yearReiterated full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA (a non-GAAP measure)VEVYE® delivered quarterly revenue of $29.4 million, up approximately 40% sequentially and approximately 58% year over year, with continued prescription, prescriber, and market-share growthVEVYE secured another coverage win, after gaining expanded formulary coverage with a top-three national commercial pharmacy benefit manager effective August 1, 2026IHEEZO® delivered quarterly revenue of $15.6 milli
- SECHarrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - HARROW, INC. (0001360214) (Filer)
- PRHarrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye DiseaseNASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is currently approved in the U.S., China, and Taiwan, with marketing authorization applications pending in other countries. This acquisition expands Harrow’s dry eye portfolio, complementing the Company's flagship VEVYE franchise by addressing dry eye
- PRHarrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the second quarter ended June 30, 2026, on Monday, August 10, 2026, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, August 11, 2026, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow’s presentation on the "Inv
- PRSamsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumabIn treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11 INCHEON, Korea and NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, presented interim data from a post-marketing surveillance (PMS) study on SB11 (US brand name: BYOOVIZ®, Korea brand
- PRHarrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual MeetingNASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO® (chloroprocaine HCl ophthalmic gel 3%), a broadly labeled low viscosity ocular anesthetic gel, and BYOOVIZ® (ranibizumab-nuna)i, an FDA-approved biosimilar referencing LUCENTISii (ranibizumab) at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. Collectively, the presentations expand the growing body of clinical and real-world evidence supporting Harrow's retina portfolio and reinforce Harrow’s commitment to generating quality evidence that strengthe
- PRSamsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with HarrowIn July 2025, Samsung Bioepis entered into partnership with Harrow for commercialization of two interchangeable ophthalmology biosimilars — BYOOVIZ® (ranibizumab-nuna) and OPUVIZ™ (aflibercept-yszy) — in the US BYOOVIZ was the first ophthalmology biosimilar to gain FDA approval in September 2021 BYOOVIZ had been previously commercialized by Biogen since June 2022, until the company returned commercial rights back to Samsung Bioepis at the end of 2025 Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (NASDAQ:HROW). Harrow became responsible for commercialization of BYOOVIZ® (ranibizumab-nuna),
- INSIDERSEC Form 4 filed by Director Sternberg Perry J.4 - HARROW, INC. (0001360214) (Issuer)
- INSIDERSEC Form 4 filed by Director Graves Adrienne L4 - HARROW, INC. (0001360214) (Issuer)
- INSIDERSEC Form 4 filed by Director Silvernail Lauren P4 - HARROW, INC. (0001360214) (Issuer)
- SECHarrow Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - HARROW, INC. (0001360214) (Filer)
- PRHarrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric EyecareVERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriersVERKAZIA is indicated for the treatment of all forms of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children and may lead to sight-threatening conditions if left untreated or undertreatedVERKAZIA is a calcineurin inhibitor immunomodulator that targets the underlying inflammatory mechanisms of VKC and may reduce the need for steroid rescue, all of which are associated with risks such as glaucoma or cataract formation NASHVILLE, Tenn., June 10, 2026 (GL
HROW FAQ
10 questionsWhat does Harrow Inc. do?
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary...What is the latest news on HROW?
In the last 30 days Quantisnow tracked 3 wire items for HROW: 2 press releases and news items and 1 earnings update. The most recent was published on November 2, 2026.What is HROW revenue?
Harrow Inc. (HROW) reported $275.59M of revenue for the twelve months ended Jun 30, 2026. That is up 21.1% from the year before. Revenue for fiscal 2025 was $272.30M.Is HROW profitable?
No. Harrow Inc. reported a net loss of $37.23M for the twelve months ended Jun 30, 2026.How much cash and debt does HROW have?
Harrow Inc. reported $83.89M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does HROW stock trade?
Harrow Inc. (HROW) is listed on NASDAQ.What sector and industry is HROW in?
Harrow Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about HROW?
Harrow Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $45.00 price target on 2026-09-09. Recent price targets range from $17.00 to $76.00.What companies are similar to HROW?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare HROW side-by-side with any of them on Quantisnow.How can I track HROW on Quantisnow?
Quantisnow aggregates Harrow Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HROW to receive live email and push alerts on every new disclosure.